• Clinical care: All our teaching health centers and practices have robust treatment programs for OUD, with all second- and third-year residents trained to provide agonist medication treatment. Our faculty provide innovative treatment access. Jeff Baxter, MD, Chief Medical Officer of Spectrum, has created bridge clinics for treatment provision, and Spectrum provides treatment in the Commonwealth’s prisons and some jails, joined by Pam Tsinteris, MD. Jay Broadhurst, MD has practiced part time at Spectrum for years. Jennifer Bradford, MD, MPH serves as medical director of all substance use disorder services at Community Health Link. With Emergency Medicine and Dr. Kavita Babu, Drs. Erik Garcia and Hugh Silk staff a treatment van supported by a SAMHSA grant. and Mohammad Alhabbal, MD is medical director at AdCare Treatment Centers. Residency graduate Heidi Ginter, MD serves as Chief Medical Officer for Recovery Centers of America. 
• Education: Thanks in large part to the pioneering efforts of Jeff Baxter, MD, medical students all receive clinical education on treatment of OUD and training starts early for students assigned to a family medicine LPP due to our robust treatment programs. Steve Martin, MD and Amber Cahill, PsyD lead a Project ECHO program focused on expanding access to MOUD. In partnership with a former behavioral health fellow, James Anderson, PhD, they published the results of the work (Anderson, 2021). Daniel Mullin, PsyD MPH completed a 3 year SAMHSA project that focused on the development of the “Care of Patients with Opioid Use Disorder” course. This course has been deployed at UMass, Tufts, and Boston University.
• Research: Robin Clark, PhD’s current work focuses on implementation of treatment for individuals with addiction in real world settings and the impact of Medicaid policies on treatment. Paula Gardiner, MD, MPH conducts research on complimentary and alternative treatment of chronic pain via medical group visits. Ekaterina Pivovarova, PhD conducts research on drug courts and their effectiveness as an alternative to incarceration and she and Warren Ferguson, MD are co-investigators on the MA-Justice Community Opioid Innovation Network with principal iInvestigators Peter Friedmann, MD, UMass-Baystate and Elizabeth Evans, PhD, UMass-Amherst School of Public Health. As noted, Dan Mullin, PsyD, MPH, director of the Center for Integrated Primary Care, is conducting research on the effectiveness of Project ECHO on access to treatment for OUD.
• Health Policy: As Governor Charlie Baker made the opioid epidemic one of his most important issues, UMMS was a pivotal ally. Dennis Dimitri, MD in his role as President of the Massachusetts Medical Society was a critical leader in supporting this work. Currently, Jennifer Bradford, MD, MPH serves as a consultant to the Office of Medicaid on substance use disorders.

• Intersectional Feminism and Reproductive Justice on 11/16/21 (specifically looking for faculty co-facilitator)
• Anti-AAPI Racism (AY21)
• Oppression Against Indigenous Peoples (AY21)
• Anti-Latinx Discrimination (AY21)
• Disability, Ableism, and Holding Medicine Accountable (AY22)
• Immigration and Colonialism (AY22)
• Medicine and the LGBTQ+ Community (AY22)

• HCV screening
• Acute HCV
• Chronic HCV: Workup
• Treatment of non-cirrhotic patients
• Treatment of cirrhotic patients
• Monitoring during treatment
• Monitoring post treatment
• "Topic by request"
• Other hepatitides in the context of HCV/Hepatitis A&B
• Treatment of special populations

• Latent TB infection testing and treatment recap
• Short course regimen considerations
• Ruling out TB disease - advanced considerations
• LTBI advanced testing and treatment considerations in special populations (i.e., pediatrics, pregnant people, liver disease)
•  CME available

• Clinical educators – MDs, DOs, NPs, PAs, RNs, Behavioral Health, Pharmacists
• Primary Care and Specialty providers
• Teachers of students, residents, and advanced learners
• Teachers in both In-patient and Ambulatory settings

• Confirmed cases 738,303; 7-day average of percent positivity is slightly down at 2.26%.
• 704 patients are hospitalized for COVID with 176 in the ICU and 98 are intubated.
• Confirmed MA deaths 18,062.
• Worcester Stop-the-Spread positivity is 8.9% (up from 7.5%).

• As of 9/20, 40 COVID- positive inpatients at the medical center (11 in ICU).
• In-house test positivity for symptomatic patients is 12.8% (down slightly for past 2 weeks); asymptomatic test positivity is 1.8%.
• 32 employees tested positive for COVID over the last 7 days (91 in September to date, already more than all of August).

• West Nile is the most common mosquito-borne disease in the United States.
• Massachusetts has its 7th case as of 9/16/21.
• Twenty-seven communities in Essex, Middlesex, Norfolk, and Suffolk counties are at high risk. Eleven additional communities are now considered at moderate risk for West Nile Virus: Fall River and Seekonk in Bristol County; North Andover in Essex County; Bridgewater, East Bridgewater, Halifax, and Plympton in Plymouth County; and Blackstone, Hopedale, Milford, and Millville in Worcester County.
• Evaluation: testing of serum or cerebrospinal fluid (CSF) to detect WNV-specific IgM antibodies.
• The incubation period can range from 2 to 14 days but the typical period is 2 to 6 days.
• Consequence: The spectrum of illness can range from asymptomatic to having a fatal neurological disease.
• The West Nile rash consists of pink spots on the arms, legs, and trunk. It looks similar to roseola or measles. Symptoms include fever, headache, and fatigue.
• Prevention: avoid mosquitos, wearing DEET mosquito repellant, wear protective clothing, and use screens on windows and doors when appropriate.
• Clinical management is supportive.

• If you have questions concerning results from a newborn screening, please contact the New England Newborn Screening Program at 774 455 4600.
• Promote newborn screens with your parents who are pregnant. Don't forget to discuss this with your patients during the prenatal period and at the hospital postpartum visit.